Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

RSV Clinical Trial

Official title:
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS

Status Completed

Clinical Trial Summary

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.

Clinical Trial Description

This randomized, double-blinded, placebo-controlled Phase 3 study will examine the immune response and the safety and tolerability profiles across 3 manufactured lots of RSVpreF when administered as a single 120 µg dose to healthy adults to demonstrate lot equivalence in manufacturing of RSVpreF. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05096208
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	October 21, 2021
Completion date	April 4, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06160128` - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System
Completed	`NCT05585632` - A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old	Phase 1
Completed	`NCT05778240` - Adherence to Palivizumab Prophylaxis	N/A
Recruiting	`NCT01985620` - The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.	N/A